Top 3 Picks
2026 Outlook
For 2026, sector trends point to accelerated AI integration in drug discovery and a pickup in FDA approvals for oncology and rare disease assets, supported by potential M&A from larger pharma players. Capital efficiency and clinical data readouts will determine winners, with the listed stocks' scores reflecting early momentum in these areas. Overall growth hinges on favorable interest rate environments unlocking further funding.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
Ginkgo Bioworks Holdings, Inc.
|
65.5 | $6.95 | $868M |
|
2
|
Vericel Corporation
|
65.0 | $40.19 | $1.6B |
|
3
|
Arcellx, Inc. Common Stock
|
61.7 | $115.07 | $4.5B |
|
4
|
Neurocrine Biosciences Inc
|
60.8 | $155.64 | $13.6B |
|
5
|
Tourmaline Bio, Inc. Common Stock
|
59.5 | -- | $1.2B |
|
6
|
Cidara Therapeutics, Inc.
|
57.3 | $221.38 | $2.4B |
|
7
|
Relay Therapeutics, Inc. Common Stock
|
55.7 | $19.04 | $917M |
|
8
|
Apogee Therapeutics, Inc. Common Stock
|
54.9 | $135.07 | $2.3B |
|
9
|
Taysha Gene Therapies, Inc. Common Stock
|
54.1 | $5.60 | $867M |
|
10
|
Recursion Pharmaceuticals, Inc. Class A Common Stock
|
53.7 | $3.63 | $2.2B |
|
11
|
Revolution Medicines, Inc. Common Stock
|
53.2 | $210.02 | $8.6B |
|
12
|
Kodiak Sciences Inc Common Stock
|
52.5 | $35.36 | $832M |
|
13
|
ImmunityBio, Inc. Common Stock
|
52.2 | $8.08 | $2.3B |
|
14
|
Anavex Life Sciences
|
52.1 | $2.86 | $774M |
|
15
|
Maze Therapeutics, Inc. Common Stock
|
52.1 | $26.21 | $1.1B |
In-Depth Analysis: Top Biotech Stocks
DNA
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and …
Ginkgo Bioworks operates the leading cell programming platform in synthetic biology, delivering end-to-end services across pharmaceuticals, food and agriculture, and industrial chemicals to accelerate organism engineering for commercial applications.
Profit margin of -219.6% and ROE of -59.9% reflect deep operating losses, while -48.5% revenue contraction signals execution challenges in scaling platform utilization and customer acquisition.
The 65.5/100 Tradestie Score indicates residual platform value that could improve with post-reorganization cost discipline by 2026. Diversified end markets position the company to capture synthetic biology demand growth once utilization rebounds, potentially narrowing losses through higher-margin service contracts and equity partnerships.
VCEL
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, …
Vericel matters in biotech as a fully integrated commercial-stage company delivering autologous cell therapies MACI for sports medicine cartilage repair and Epicel for severe burn care, targeting specialized regenerative markets with limited competition.
Vericel's 7.9% profit margin and 7.2% ROE reflect early-stage profitability, while 22.5% revenue growth demonstrates strong commercial traction despite the high 84.3 P/E ratio indicating elevated growth expectations.
With 22.5% revenue growth and a 65.0/100 Tradestie Score, VCEL offers upside for 2026 as MACI and Epicel adoption scales in sports medicine and burn care. Margin expansion beyond 7.9% combined with ROE improvement above 7.2% could support multiple compression from the current 84.3 P/E as the company matures.
ACLX
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Arcellx matters in the Biotech sector as a clinical-stage company advancing novel cell therapies and immunotherapies for Multiple Myeloma, Acute Myeloid Leukemia, solid tumors, and non-oncology indications, targeting high-unmet-need cancers and incurable diseases.
Arcellx reports ROE of -53.4% and revenue growth of -89.2%, reflecting typical clinical-stage biotech losses driven by R&D spend with minimal revenue, indicating heavy cash burn and reliance on external financing for pipeline development.
Arcellx's focused pipeline in Multiple Myeloma and AML offers catalysts for clinical data readouts that could drive significant upside in 2026 as a pre-commercial biotech. The Tradestie Score of 61.7/100 signals baseline market attention that may expand with positive trial outcomes, supporting potential re-rating on proof-of-concept in cell therapy.
NBIX
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat …
Neurocrine Biosciences matters in the Biotech sector as a specialist in neurological and endocrine disorders, with INGREZZA established as a leading treatment for tardive dyskinesia and Huntington's chorea.
Neurocrine's 20.9% profit margin and 22.1% ROE reflect strong profitability and efficient capital returns, while 39.5% revenue growth demonstrates accelerating commercial traction.
At a P/E of 23.2 alongside 39.5% revenue growth, NBIX appears reasonably valued for its expansion trajectory in 2026. Continued INGREZZA uptake in movement disorders and the 60.8/100 Tradestie Score position the stock for further gains as the neurological pipeline matures.
TRML
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The …
Tourmaline Bio matters in Biotech as a late-stage clinical company advancing TOUR006, a fully human monoclonal antibody selectively targeting immune diseases with high unmet need.
Limited financial data indicate Tourmaline Bio is pre-revenue and unprofitable, with financial health reliant on external capital to sustain R&D through clinical trials.
TRML offers upside in 2026 if TOUR006 delivers positive late-stage data, enabling potential approvals or partnerships in immune disease markets. The 59.5/100 Tradestie Score reflects moderate pipeline momentum that could accelerate valuation upon clinical catalysts.
CDTX
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Cidara Therapeutics matters in the Biotech sector through its clinical-stage CD388 DFC asset targeting influenza prophylaxis, offering a novel immunotherapeutic approach to improve standards of care for serious infectious diseases.
ROE of -68.7% and revenue growth of -100% reflect heavy R&D spending in a pre-revenue clinical-stage biotech with no commercial products, signaling ongoing cash burn typical of early development pipelines.
CDTX could appeal to investors in 2026 if CD388 advances through key trials with positive prophylaxis data, capturing share in the influenza market. The Tradestie Score of 57.3/100 provides a moderate foundation for upside as portfolio approaches transform existing treatments. Clinical progress on its immunotherapeutic platform may drive valuation re-rating ahead of potential regulatory milestones.
RLAY
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline …
Relay Therapeutics matters in Biotech for its Dynamo platform, which combines computational and experimental technologies to accelerate precision medicine drug discovery and deliver targeted therapies more efficiently than conventional approaches.
ROE of -36.8% and revenue growth of -48.3% reflect typical clinical-stage biotech losses driven by heavy R&D investment and lack of approved products, signaling ongoing cash burn and weak top-line performance.
Investors should consider RLAY in 2026 as the Dynamo platform advances multiple precision oncology candidates toward clinical milestones that could unlock milestone payments or partnerships. A Tradestie Score of 55.7/100 indicates moderate market positioning that may improve with positive trial data, positioning the stock for re-rating ahead of potential revenue inflection despite current negative metrics.
APGE
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life …
Apogee Therapeutics develops differentiated biologics targeting atopic dermatitis, COPD, and related I&I indications with high unmet need, positioning it as a focused player in the inflammatory and immunology segment of the Biotech sector.
The company's ROE of -32.5% reflects ongoing R&D-driven losses typical of clinical-stage biotechs, while its Tradestie Score of 54.9/100 indicates average financial health amid pre-commercial operations.
Investors should consider APGE in 2026 as pipeline antibody programs advance toward potential clinical milestones in AD and COPD, offering upside from differentiated mechanisms in large addressable markets. Positive data readouts could drive valuation re-rating and improve ROE from the current -32.5% level through partnerships or commercialization. The Tradestie Score of 54.9/100 provides a baseline for monitoring operational progress in high-need I&I indications.
TSHA
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a …
Taysha Gene Therapies develops AAV-based gene therapies for monogenic CNS diseases affecting both rare and large patient populations, targeting high-unmet-need areas in biotech with potential to modify disease progression at the genetic level.
Taysha reports an ROE of -47.1%, reflecting ongoing net losses typical of clinical-stage gene therapy developers with heavy R&D spend. Its 171.3% revenue growth indicates early traction from collaborations or initial product contributions that could support balance sheet expansion.
TSHA's pipeline focus on CNS gene therapies combined with 171.3% revenue growth positions it for clinical and commercial milestones by 2026 that could accelerate cash flows. A Tradestie Score of 54.1/100 leaves room for re-rating if upcoming data readouts validate efficacy in larger indications. Investors may see upside from pipeline advancement as the company scales beyond current negative profitability.
RXRX
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Recursion Pharmaceuticals integrates technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery, positioning it as a leader in accelerating clinical-stage biotech pipelines.
The company reports a ROE of -56.6% and revenue growth of -60.1%, reflecting heavy R&D investments and typical pre-commercial losses for a clinical-stage biotech with no approved products.
Recursion's platform could generate multiple clinical readouts and partnerships by 2026, driving revenue inflection through industrialized drug development. Its Tradestie Score of 53.7/100 offers room for re-rating as data science-driven candidates advance. Investors may benefit from sector tailwinds in AI-enabled biotech as the company scales its automation and engineering capabilities.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.